Ribon Therapeutics is a technology company.
Ribon Therapeutics has raised $164.0M across 4 funding rounds.
Ribon Therapeutics has raised $164.0M in total across 4 funding rounds.
Ribon Therapeutics has raised $164.0M in total across 4 funding rounds.
Ribon Therapeutics's investors include Canaan Partners, Deerfield Management, Hercules Capital, Johnson & Johnson Innovation, MPM Capital, Osage University Partners.
Ribon Therapeutics is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing novel small-molecule therapeutics that target stress support pathways and enzyme families activated under cellular stress conditions, particularly for cancer and inflammatory diseases.[1][2][3] The company aims to create first-in-class treatments for patients with limited options, with key programs including RBN-3143, an oral PARP14 inhibitor showing preclinical efficacy in lung inflammation models, and has raised $251.5 million across seven funding rounds, including a $65 million round in 2021 and a $25 million most recent raise.[3][4]
Ribon serves patients in oncology and immunology, addressing unmet needs in diseases driven by cellular stress responses where traditional therapies fall short.[1][2][3] Growth momentum included strong investor backing from firms like Peregrine Ventures and partnerships or support from major pharma players such as AbbVie, BMS, J&J, Novartis, and Pfizer, though the company ceased operations in August 2024 after nearly a decade.[2][3][4]
Ribon Therapeutics emerged in the biotech hub of Cambridge, Massachusetts, with early momentum from seed-stage funding and a focus on novel PARP inhibitors and stress pathway targets.[3][4] Key leadership included CEO Victoria Richon, who in 2021 highlighted investor excitement for advancing first-in-class candidates in interviews following a $65 million raise.[4] Pivotal moments featured preclinical data presentations, such as the 2023 late-breaking poster on RBN-3143's anti-inflammatory potential, alongside expansions and trial progress noted in 2019-2021 industry reports.[3][4] The company's trajectory built on high-profile pharma support but culminated in shutdown amid challenges for PARP-focused biotechs.[4]
Ribon rode the wave of precision oncology and immunology trends, capitalizing on cellular stress pathways as a frontier for small-molecule innovation amid rising demand for targeted therapies beyond traditional checkpoints.[1][2][3] Timing aligned with PARP inhibitor hype post-major approvals, but market forces like clinical setbacks in similar modalities contributed to its 2024 shutdown, highlighting risks in niche enzyme targeting.[4] Ribon influenced the ecosystem by validating stress-support pathways, attracting pharma interest, and demonstrating how VC-backed biotechs can advance preclinical assets to clinical stages, even if short-lived.[3][4]
Ribon's story underscores biotech volatility: bold science in stress pathways garnered elite funding and data milestones, yet PARP challenges led to closure by August 2024, with no ongoing operations.[4] Assets like RBN-3143 may get acquired by partners (e.g., AbbVie, Pfizer), perpetuating impact in inflammation and oncology.[3][4] Trends like AI-driven target discovery and combo therapies could revive similar platforms, but Ribon's arc warns of execution risks—echoing its opening promise of novel treatments now absorbed into the broader pharma pipeline.[1][4]
Ribon Therapeutics has raised $164.0M across 4 funding rounds. Most recently, it raised $65.0M Series C in June 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2021 | $65.0M Series C | Canaan Partners, Deerfield Management, Hercules Capital, Johnson & Johnson Innovation, MPM Capital, Osage University Partners | |
| Jan 1, 2019 | $65.0M Series B | Canaan Partners, Johnson & Johnson Innovation, Osage University Partners | |
| Jan 1, 2016 | $24.0M Series A | Canaan Partners, Johnson & Johnson Innovation, Osage University Partners | |
| Dec 1, 2015 | $10.0M Venture Round | Canaan Partners, Johnson & Johnson Innovation, Osage University Partners |